We maintain our USD 258 fair value estimate for narrow-moat ResMed RMD, or AUD 40 per CDI at current exchange rates, following first-quarter fiscal 2024 results. Underlying EBIT of USD 319 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback